Company
Insmed Incorporated
Headquarters: Bridgewater, NJ, United States
Employees: 613
CEO: Mr. William H. Lewis J.D., M.B.A.
Market Cap
$13.93 Billion
USD as of Jan. 1, 2025
Insmed Incorporated Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $343.0 M |
| EBITDA | $-695,056,000 |
| Gross Profit TTM | $264.9 M |
| Profit Margin | -252.01% |
| Operating Margin | -212.73% |
| Quarterly Revenue Growth | 18.20% |
Stocks & Indices
Insmed Incorporated has the following listings and related stock indices.
Stock: NASDAQ: INSM wb_incandescent
Stock: FSX: IM8N wb_incandescent